This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): SFVeE6,7
Description: ViciniVax developed Vvax001 based on an attenuated, recombinant Semliki Forest virus (SFV). Vvax001 is a therapeutic cancer vaccine against (pre)malignant cervical lesions.
ViciniVax and Intravacc
In March 2013, Intravacc, the Institute for Translational Vaccinology, and ViciniVax announced that they signed a license agreement on the use of Intravaccs Vero production cell line for vaccine development.
Under the terms of the agreement, ViciniVax will have a non-exclusive license to use the Vero cell line platform technology of Intravacc for development of a therapeutic vaccine against cervical cancer Vvax001. In addition, ViciniVax will receive master and working cell banks.
Partners: Intravacc (Institute for Translational Vaccinology)
Additional information available to subscribers only: